z-logo
open-access-imgOpen Access
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Author(s) -
Ania Wajnberg,
Fatima Amanat,
Adolfo Firpo,
Deena R. Altman,
Mark Bailey,
Mayce Mansour,
Meagan McMahon,
Philip Meade,
Damodara Rao Mendu,
Kimberly Muellers,
Daniel Stadlbauer,
Kimberly Stone,
Shirin Strohmeier,
Viviana Simon,
Judith A. Aberg,
David L. Reich,
Florian Krammer,
Carlos CordonCardo
Publication year - 2020
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.abd7728
Subject(s) - covid-19 , virology , antibody , betacoronavirus , medicine , sars virus , neutralizing antibody , coronavirus infections , immunology , biology , outbreak , infectious disease (medical specialty) , disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom